Resistance to platinum compounds: mechanisms and beyond.
Kelley
S L
SL
Department of Clinical Cancer Research, Bristol-Myers Pharmaceutical Research and Development Division, Wallingford, CT 06492.
Rozencweig
M
M
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin; D002945:Cisplatin / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D009944:Organoplatinum Compounds / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D016190:Carboplatin; D002945:Cisplatin